You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors
|
|---|---|
| Published in |
Investigational New Drugs, October 2006
|
| DOI | 10.1007/s10637-006-9017-4 |
| Pubmed ID | |
| Authors |
Luis H. Camacho, Jon Olson, William P. Tong, Charles W. Young, David R. Spriggs, Mark G. Malkin |
| Abstract |
Phenylbutyrate (PBA), and its metabolite phenylacetate (PAA), induce growth inhibition and cellular differentiation in multiple tumor models. However, despite their potential anti-cancer properties, several pharmacodynamic aspects remain unknown. |
Mendeley readers
The data shown below were compiled from readership statistics for 52 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 2% |
| Unknown | 51 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 17% |
| Student > Bachelor | 8 | 15% |
| Student > Ph. D. Student | 8 | 15% |
| Professor > Associate Professor | 4 | 8% |
| Lecturer | 2 | 4% |
| Other | 5 | 10% |
| Unknown | 16 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 27% |
| Agricultural and Biological Sciences | 6 | 12% |
| Biochemistry, Genetics and Molecular Biology | 4 | 8% |
| Psychology | 4 | 8% |
| Nursing and Health Professions | 3 | 6% |
| Other | 4 | 8% |
| Unknown | 17 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 24. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 February 2024.
All research outputs
#1,321,330
of 22,757,090 outputs
Outputs from Investigational New Drugs
#22
of 1,168 outputs
Outputs of similar age
#2,271
of 67,087 outputs
Outputs of similar age from Investigational New Drugs
#1
of 5 outputs
Altmetric has tracked 22,757,090 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,168 research outputs from this source. They receive a mean Attention Score of 4.7. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 67,087 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them